全文获取类型
收费全文 | 871篇 |
免费 | 122篇 |
国内免费 | 89篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 5篇 |
妇产科学 | 12篇 |
基础医学 | 96篇 |
口腔科学 | 6篇 |
临床医学 | 137篇 |
内科学 | 140篇 |
皮肤病学 | 6篇 |
神经病学 | 22篇 |
特种医学 | 29篇 |
外国民族医学 | 1篇 |
外科学 | 206篇 |
综合类 | 114篇 |
预防医学 | 23篇 |
眼科学 | 11篇 |
药学 | 143篇 |
中国医学 | 5篇 |
肿瘤学 | 96篇 |
出版年
2024年 | 11篇 |
2023年 | 67篇 |
2022年 | 88篇 |
2021年 | 68篇 |
2020年 | 59篇 |
2019年 | 47篇 |
2018年 | 34篇 |
2017年 | 27篇 |
2016年 | 19篇 |
2015年 | 32篇 |
2014年 | 81篇 |
2013年 | 70篇 |
2012年 | 78篇 |
2011年 | 112篇 |
2010年 | 85篇 |
2009年 | 51篇 |
2008年 | 34篇 |
2007年 | 29篇 |
2006年 | 18篇 |
2005年 | 18篇 |
2004年 | 15篇 |
2003年 | 11篇 |
2002年 | 6篇 |
2001年 | 2篇 |
2000年 | 3篇 |
1999年 | 3篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 2篇 |
1989年 | 2篇 |
1984年 | 1篇 |
1982年 | 1篇 |
1981年 | 1篇 |
排序方式: 共有1082条查询结果,搜索用时 15 毫秒
1.
2.
二甲双胍对多囊卵巢综合征患者胰岛素样生长因子-1的影响 总被引:2,自引:0,他引:2
目的探讨二甲双胍对多囊卵巢综合征(PCOS)患者血清胰岛素样生长因子-1(IGF-1)及胰岛素样生长因子结合蛋白-1(IGFBP-1)水平的影响及其作用机制,明确二甲双胍治疗的临床效果。方法2002年1—11月对山西医科大学第二医院24例PCOS患者给予二甲双胍500mg,一日3次,8~24周治疗,比较治疗前后血清IGF-1、IGFBP-1、空腹胰岛素及睾酮水平,并对月经恢复、排卵、妊娠情况进行分析。结果二甲双胍可降低血清空腹胰岛素及睾酮水平,能显著升高IGFBP-1水平,治疗前后血清IGF—1水平差异无显著性。单纯二甲双胍治疗后月经恢复率为41.67%(10/24);自然排卵率为25.00%(6/24),自然妊娠率为12.50%(3/24)。二甲双胍加促排卵治疗共18个周期,排卵周期率66.67%(12/18),妊娠周期率为11.11%(2/18)。结论二甲双胍可以降低血清空腹胰岛素及睾酮水平,增高IGFBP-1水平,可以改善卵泡微环境,有助于月经恢复,提高促排卵和妊娠率.是治疗PCOS的重要手段。 相似文献
3.
Jinyi Yuan Biwen Mo Zhuang Ma Yuan Lv Shih-Lung Cheng Yanping Yang Zhaohui Tong Renguang Wu Shenghua Sun Zhaolong Cao Jufang Wu Demei Zhu Liwen Chang Yingyuan Zhang 《Journal of microbiology, immunology, and infection》2019,52(1):35-44
Background/Purpose
Nemonoxacin is a novel nonfluorinated quinolone with excellent in vitro activity against most pathogens in community-acquired pneumonia (CAP), especially Gram-positive isolates. The purpose of this study was to assess the efficacy and safety of nemonoxacin compared with levofloxacin in patients with CAP.Methods
A phase 3, multicenter, randomized (2:1) controlled trial was conducted in adult CAP patients receiving nemonoxacin 500 mg or levofloxacin 500 mg orally once daily for 7–10 days. Clinical, microbiological response and adverse events were assessed. Non-inferiority was determined in terms of clinical cure rate of nemonoxacin compared with that of levofloxacin in a modified intention-to-treat (mITT) population. NCT registration number: NCT01529476.Results
A total of 527 patients were randomized and treated with nemonoxacin (n = 356) or levofloxacin (n = 171). The clinical cure rate at test-of-cure visit was 94.3% (300/318) for nemonoxacin and 93.5% (143/153) for levofloxacin in the mITT population [difference (95% CI), 0.9% (?3.8%, 5.5%)]. The microbiological success rate was 92.1% (105/114) for nemonoxacin and 91.7% (55/60) for levofloxacin in the bacteriological mITT population [difference (95% CI), 0.4% (?8.1%, 9.0%)]. The incidence of adverse events (AEs) was comparable between nemonoxacin (33.1%, 118/356) and levofloxacin (33.3%, 57/171) (P > 0.05).Conclusion
Nemonoxacin 500 mg once daily for 7–10 days is as effective and safe as levofloxacin for treating adult CAP patients in terms of clinical cure rates, microbiological success rates, and safety profile.ClinicalTrials.gov identifier: NCT01529476. 相似文献4.
Washed microbiota transplantation stopped the deterioration of amyotrophic lateral sclerosis: The first case report and narrative review
下载免费PDF全文
![点击此处可从《生物医学研究杂志》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Amyotrophic lateral sclerosis (ALS) is known as a progressive paralysis disorder characterized by degeneration of upper and lower motor neurons, and has an average survival time of three to five years. Growing evidence has suggested a bidirectional link between gut microbiota and neurodegeneration. Here we aimed to report one female case with ALS, who benefited from washed microbiota transplantation (WMT), an improved fecal microbiota transplantation (FMT), through a transendoscopic enteral tube during a 12-month follow-up. Notedly, the accidental scalp trauma the patient suffered later was treated with prescribed antibiotics that caused ALS deterioration. The subsequent rescue WMTs successfully stopped the progression of the disease with a quick improvement. The plateaus and reversals occurred during the whole course of WMT. The stool and blood samples from the first WMT to the last were collected for dynamic microbial and metabolomic analysis. We observed the microbial and metabolomic changing trend consistent with the disease status. This case report for the first time shows the direct clinical evidence on using WMT for treating ALS, indicating that WMT may be the novel treatment strategy for controlling this so-called incurable disease. 相似文献
5.
《Vaccine》2021,39(18):2537-2544
BackgroundAlthough the efficacy of hepatitis B vaccines among hemodialysis patients has been documented, the long-term persistence of immunogenicity in this population remains largely unknown. We explored the long-term persistence of immunogenicity induced by different hepatitis B vaccine regimens in hemodialysis patients.MethodsIn initial study, we conducted a randomized, multicenter, double-blind, parallel-controlled trial among hemodialysis patients in 13 hospitals in Shanxi Province, China. A total of 352 hemodialysis patients were allocated to receive 3-dose 20 μg (IM20 group) and 3-dose 60 μg (IM60 group) recombinant hepatitis B vaccine at months 0, 1, and 6. Vaccine-induced immune responses were measured at month 7. In this study, the responders (anti-HBs ≥ 10 mIU/mL) were followed up at months 18, 24, 30, 36 and 42, respectively. We used the generalized log-rank test and generalized estimating equations (GEE) to analyze the long-term durability of responses and the kinetics of anti-HBs levels, respectively.ResultsA total of 284 patients were involved in the extended follow-up period. The duration of vaccine-induced response with 75% of patients maintained protective antibody were 12 months and 18 months in the IM20 group and IM60 group, respectively (P = 0.291). The long-term persistent immunogenicity induced by 3-dose 60 μg was more satisfactory than that by 3-dose 20 μg hepatitis B vaccine in patients with hemodialysis duration ≥ five years (P = 0.023). The peak anti-HBs levels in 100–1000 mIU/mL or ≥ 1000 mIU/mL were more likely to maintain long-term protective antibody compared to anti-HBs levels in 10–100 mIU/mL (P < 0.05). The kinetic profile was similar between the two groups (P = 0.334).ConclusionHigh-dose 60 μg hepatitis B vaccine could lead a satisfactory long-term durability of immunogenicity among patients with hemodialysis duration of five years or more. Peak anti-HBs level after vaccination was associated with the long-term persistence of immunogenicity. 相似文献
6.
《Autoimmunity reviews》2023,22(2):103264
Idiopathic inflammatory myopathies (IIM) are a group of different conditions typically affecting striate muscle, lung, joints, skin and gastrointestinal tract. Treatment typically relies on glucocorticoids and synthetic immunosuppressants, but the occurrence of refractory, difficult to treat, manifestations, may require more aggressive treatment, borrowed from other autoimmune diseases, including biologic disease modifying drugs (bDMARDs). In this regard, we conducted a systemic literature review in order to depict the current evidence about the use of bDMARDs in IIM. A total of 78 papers, published during the last 21 years, were retrieved. The majority of patients was treated with TNF-α inhibitors, whose effectiveness was assessed particularly in recalcitrant striate muscle, skin and joints involvement. Rituximab, whose evidence is supported by a large number of real-life studies and trials, seems to be an excellent option in case of ILD and anti-synthetase syndrome, while Tocilizumab, despite not meeting primary and secondary endpoints in a recently published clinical trial, proved its effectiveness in rapidly progressing ILD. Similarly, Abatacept, studied in a phase IIb clinical trial with conflicting evidence, was reported to be effective in some case reports of refractory dermatomyositis. Less data exist for anti-IL1 and anti-IL23 agents, which were employed particularly for inclusion body myositis and severe skin disease, respectively. This study provides an organ-focused assessment of bDMARDs in IIM, which display encouraging results in the treatment of refractory subsets of disease. 相似文献
7.
《Autoimmunity reviews》2023,22(3):103260
Exosomes are spherical lipid bilayer vesicles composed of lipids, proteins and nucleic acids that deliver signaling molecules through a vesicular transport system to regulate the function and morphology of target cells, thereby involving in a variety of biological processes, such as cell apoptosis or proliferation, and cytokine production. In the past decades, there are emerging evidence that exosomes play pivotal roles in the pathological mechanisms of several autoimmune diseases (ADs), including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes mellitus (T1DM), Sjogren's syndrome (SS), multiple sclerosis (MS), inflammatory bowel disease (IBD). systemic sclerosis (SSc), etc. Several publications have shown that exosomes are involved in the pathogenesis of ADs mainly through intercellular communication and by influencing the response of immune cells. The level of exosomes and the expression of nucleic acids can reflect the degree of disease progression and are excellent biomarkers for ADs. In addition, exosomes have the potential to be used as drug carriers thanks to their biocompatibility and stability. In this review, we briefly summarized the current researches regarding the biological functions of exosomes in ADs, and provided an insight into the potential of exosomes as biomarkers and therapeutic delivery for these diseases. 相似文献
8.
《Autoimmunity reviews》2023,22(3):103270
BackgroundIt is now accepted that immune tolerance disorders caused by inadequate Treg cell function or number are important factors in the development and progression of rheumatic diseases. There is increasing evidence that ld IL-2 treatment increases the proportion of Treg cells in patients' peripheral blood, but this conclusion is still controversial. Here, we performed a meta-analysis of reports documenting the proportion of Treg cells and the rate of adverse events in patients with rheumatic disease before and after the administration of ld IL-2 to better understand its effect and safety on Treg cells in the field of rheumatic diseases.MethodsWe systematically searched PubMed, Embase, Scopus, Cochrane Library, and Web of science databases up to 15th November 2022 and identified studies that reported the proportion of peripheral blood Treg cells before and after ld IL-2 treatment in patients with rheumatic disease. Random-effects model was used to perform a meta-analysis of Treg cell proportions before and after ld IL-2 administration, and a meta-regression analysis was performed to explore heterogeneity. Inconsistency was evaluated using the I-squared index (I2), and publication bias was assessed by examining funnel plot asymmetry using the Egger tests.ResultsEighteen studies involving 1608 patients were included in the meta-analysis. The proportion of Treg cells in peripheral blood of these patients increased significantly after receiving ld IL-2 treatment [1.07 (95% CI 0.86,1.27), p < 0.001, I2 = 67.3%]. Next, Meta-regression was performed for 5 variables including publish year, disease type, trail type and dosage and duration of the medication. The results suggest that these variables do not lead to high heterogeneity. (p = 0.698, 0.267, 0.502, 0.843, 0.560, respectively). And finally, statistical analysis showed no difference in adverse reactions between ld IL-2 group and control group in treatment [1.06 (95% CI 0.86,1.31), p = 0.586, I2 = 53.8%], which is unreliable because the data is so small.ConclusionsLd IL-2 does increase the proportion of peripheral blood Treg cells in patients with rheumatism, and single and cumulative doses must be considered when using ld IL-2. In addition, more studies on the safety of ld IL-2 are urgently needed. 相似文献
9.
对用消费者权益保护法处理医疗纠纷的不同见解 总被引:4,自引:0,他引:4
我们针对社会上要求运用消费者权益保护法保护患者权益的舆论,从3 个方面阐述了我们的不同见解:①我国卫生事业的性质决定了医院不是提供商品性消费服务的“经营者”;②患者接受对疾病的诊疗过程中的被动地位,及得到的诊疗服务不是等价交换,决定了患者不是接受一般服务的“消费者”;③由于医疗工作的不可完全预见后果的高风险性和医务人员无私奉献,诊疗服务不是一般的“服务”。因此,我们建议尽快专门立法,规范医患关系,处理医患纠纷 相似文献
10.
目的检测鼻炎胶囊的有效性和急性毒性反应,为临床提供现代药理学及安全用药的科学依据。方法①药效学实验:4组实验动物,每组40只,随机分成大剂量鼻炎胶囊组、小剂量鼻炎胶囊组、阳性对照组(鼻炎康或阿司匹林)和空白对照组,每组各10只。分别灌胃给药,观察该药对小鼠二甲苯性耳壳炎症、冰醋酸致痛作用及冰醋酸致腹腔毛细血管通透性增高和大鼠棉球肉芽肿的影响。②急性毒性实验:20只小鼠灌胃给予最大浓度和最大剂量鼻炎胶囊溶液,用药24 h和1周后观察动物的一切行为活动及各主要脏器的外观形态。结果与空白对照组相比,大、小剂量鼻炎胶囊组对小鼠二甲苯性耳壳炎症、冰醋酸致痛作用及其腹腔注射后导致毛细血管通透性增高和大鼠棉球肉芽肿均有抑制作用(P<0.05),大剂量鼻炎胶囊组作用更强。急性毒性实验显示小鼠未见任何异常,无死亡,主要脏器外观形态无异常。结论该药可减轻小鼠二甲苯性耳壳炎症及降低冰醋酸腹腔注射后毛细血管的通透性和抑制大鼠棉球肉芽肿,并有止痛作用。急性毒性实验表明该药无毒性,安全性好。 相似文献